Global /Taiwan /Healthcare /Medical Distribution /6617

Gongwin Biopharm Holdings Co., Ltd.

6617

• TPEX: 6617 • Delayed

74.90TWD -0.7%

2.37 USD

As of 12 June 2026, Gongwin Biopharm Holdings Co., Ltd. has a market cap of $291.75M USD, ranking #18740 globally and #760 in Taiwan. It ranks #1694 in the Healthcare sector, and #62 in the Medical Distribution industry.

Global Rank

18740

Country Rank

760

Sector Rank

1694

Industry Rank

Key Stats

Market Cap

$291.75MUSD

9.25B TWD

Enterprise Value

$243.53MUSD

7.7B TWD

Revenue (TTM)

$1.15MUSD

36.45M TWD

EBITDA (TTM)

-$6.28MUSD

-198.59M TWD

Net Income (TTM)

-$3.6MUSD

-114.13M TWD

PS Ratio

253.7

PB Ratio

3.7

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Medical Distribution

CEO

Mao-Yuan Lin open_in_new

Founded

2014

Website

gongwinbiopharm.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.7%	24%	10%	-3.6%	-22%	-13%	-24%	-77%	-58%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	6617 共信醫藥科技控股股份有限公司 ISIN: KYG409471060 Shares Out.: Shares Outstanding: 121.21M¹ Shares Float: 61.076M² TV: TradingView: TPEX: 6617 SA: Stock Analysis: TPEX: 6617 YF: Yahoo Finance: 6617.TWO GF: Google Finance: TPEX: 6617 BA: Barron's: 6617 MS: Morningstar: ROCO: 6617	74.90 TWD	TV: TradingView: TPEX: 6617 SA: Stock Analysis: TPEX: 6617 YF: Yahoo Finance: 6617.TWO GF: Google Finance: TPEX: 6617 BA: Barron's: 6617 MS: Morningstar: ROCO: 6617

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Similar Companies

Industry: Medical Distribution (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Excelsior Medical Co., Ltd. TWSE: 4104	$386.55M 12.25B TWD 32%	15.3	Taiwan
CHC Healthcare Group TWSE: 4164	$181.5M 5.75B TWD -38%	29.5	Taiwan
WeLeader Biomedical Co., Ltd. TPEX: 7713	$96.87M 3.07B TWD -67%	14.9	Taiwan
ShareHope Medicine Co., Ltd. TPEX: 8403	$93.6M 2.97B TWD -68%	20.9	Taiwan
Eyecare Tech Inc. TPEX: 7881	$81.79M 2.59B TWD -72%	-	Taiwan
Norbel Baby Co., Ltd. TPEX: 6844	$76.41M 2.42B TWD -74%	27.6	Taiwan

Industry: Medical Distribution (Global)

Name	Market Cap (USD) diff.	PE	Country
McKesson Corp. NYSE: MCK	$100.76B 34K%	24.0	United States
Cencora, Inc. NYSE: COR	$60.58B 21K%	37.4	United States
Cardinal Health, Inc. NYSE: CAH	$47.73B 16K%	29.6	United States
Henry Schein, Inc. NASDAQ: HSIC	$8.47B 3K%	22.6	United States
Sinopharm Group Co. Ltd. SHEK: 1099	$7.48B 58.61B HKD 2K%	7.2	China
Galenica AG SIX: GALE	$5.26B 4.2B CHF 2K%	23.0	Switzerland

chevron_leftBack